期刊文献+

2型糖尿病经格列美脲治疗的有效性及药理探究 被引量:2

Effectiveness and Pharmacology of Glimepiride in the Treatment of Type 2 Diabetes Mellitus
下载PDF
导出
摘要 目的:分析格列美脲治疗2型糖尿病的效果及药理作用。方法:随机选择2014年11月~2016年11月在某院接受治疗的2型糖尿病患者50例参与研究,随机平均分成两组,对照组利用药物格列齐特治疗,观察组选择药物格列美脲治疗,比较两组效果。结果:观察组治疗总有效率为96%,对照组总有效率为68%;观察组治疗后HbA1c、2hPG、FPG水平明显低于对照组(P<0.05)。结论:格列美脲治疗2型糖尿病效果明显,能够明显改善血糖水平,不会影响治疗安全性,值得推广。 Objective:To analyze the effect and pharmacology of glimepiride in the treatment of type 2 diabetes.Methods:50 patients with type 2 diabetes treated in a hospital from November 2014 to November 2016 were randomly selected and divided into two groups.The control group was given drug gliclazide treatment, and the observation group was given drug glimepiride treatment,then the effect between the two groups was compared.Results:The total effective rate of observation group was 96%, the total effective rate of control group was 68%, and the HbAlc, 2hPG and FPG levels in the observation group were significantly lower than those in the control group (P〈0.05).Conclusion:Gglimepiride in the treatment of type 2 diabetes has obvious effect,which can significantly improve the blood glucose level,will not affect the safety of the treatment, and is worthy of promotion.
作者 李志铭
出处 《数理医药学杂志》 2018年第1期87-88,共2页 Journal of Mathematical Medicine
关键词 2型糖尿病 格列美脲 有效性 药理 type 2 diabetes mellitus glimepiride effectiveness pharmacology
  • 相关文献

参考文献6

二级参考文献46

  • 1李霞,周智广,亓海英,陈小燕,黄干.用空腹C肽代替胰岛素改良Homa公式评价胰岛素抵抗和胰岛β细胞功能[J].中南大学学报(医学版),2004,29(4):419-423. 被引量:212
  • 2姚晔.格列美脲联合盐酸二甲双胍对2型糖尿病疗效分析[J].药物与临床,2012,2(2):110.
  • 3Alvarsson M,Sundkvist G,Lager I,el al.Effects of insulin vs glib-enclamide in recently diagnosed patients with type 2 diabetes:a 4-year follow-up[J].Diabetes Obes Metab,2008;10:421-9.
  • 4Schwartz S,Ruskin P,Fonseca V,et al.Effect troglitazone in insulin trea-ted patients with typeⅡdiabetes mellitus.Troglitazone and Exogenous In-sulin Study Group[J].N Engl J Med,1998;338:861-6.
  • 5Briscoe V J, Griffith ML, Davis SN. The role of glimepiride in the treatmeat of type 2 diabetes mellitus [J]. Expert Opin Drug Metab Toxicol, 2010, 6(2): 225-235.
  • 6Luis B J, Bugos C, DimbergerG, et al. Efficacy and safety profile of Glimepiridein Mexican American patients with type 2 diates melli- ms: a randomized placebo-controlled study [J]. Clinical Therapeu- tics, 2003, 25(1): 194-209.
  • 7Del Prato S, Felton AM, Muntro N, et al. Improving glucose management: ten steps to get more patients with type 2 diabe tes to glycaemic goal [J]. Int J Clin Pract, 2005, 59 (11): 1345-1355.
  • 8Stratton IM, Adler AI, Neil HA, et al. Association of glyce- mla with macrovascular and micmvascular complications of type 2 (UKPDS 35) :diabetes: prospective observational study [J]. BMJ, 2000, 321(12): 405-412.
  • 9Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic micmvascular complications in diabetes mellitus[J]. Ann Intern Med, 1996, 124(IPt2): 90-96.
  • 10Korytkowski M, Thomas A, Reid L, et al. Glimepiride im- proves both first and second phases of insulin secretion in type2 diabetes[J]. Diabetes Care, 2002,25 : 1607-1611.

同被引文献7

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部